Oligonucleotide (Antisense oligonucleotide) · Gene silencing · developed by CAMP4 Therapeutics
CMP-002 is an antisense oligonucleotide administered by intrathecal injection. It is studied in nervous system diseases.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07935135 | Phase 1/2 | Nervous System Disease | Not yet recruiting | CAMP |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Nervous System Disease
Updated Nov 15, 2026. Something wrong or missing? Report it on the CAMP page.
See CAMP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CAMP catalysts and pipeline →